Sarepta Therapeutics, Inc. (0L35.L)
| Previous close | 124.82 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 97.532M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Sarepta Therapeutics...
- Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
- Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
There are many such corporations to consider on the market, but let's examine two: Guardant Health (NASDAQ: GH) and Sarepta Therapeutics (NASDAQ: SRPT). Progress in cancer research is always important as cancer is a leading cause of death worldwide. Guardant Health focuses on developing liquid biopsies -- tests that help detect signs of cancer from blood samples.
